Opendata, web and dolomites

DIA-VIT

DIA-VIT, a non-invasive glucose self-monitoring device for diabetes patients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "DIA-VIT" data sheet

The following table provides information about the project.

Coordinator
VB CENTER D.O.O. 

Organization address
address: ZAMUSANI 100A
city: GORISNICA
postcode: 2272
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Slovenia [SI]
 Project website http://dia-vit.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VB CENTER D.O.O. SI (GORISNICA) coordinator 50˙000.00

Map

 Project objective

DIA-VIT is a first non-invasive glucose self-monitoring device for diabetes patients, with proven operational results. We have designed and produced our own unique innovative modules and developed the algorithm supporting the device. Our device was tested and proved in relevant environment and is at TRL 6 stage according to Technology Readiness Level table.

Technology of DIA-VIT device is extremely disruptive by nature. Although there have been several trials over the years, technology for monitoring glucose has not changed for more than 30 years. All existing technologies are invasive.

Key market application of our device is direct replacement of current generation of self-monitoring devices for glucose measurement. On the basis of the patent search we believe that we have freedom to operate and that we do not breach any other patent rights.

Today 387 million people in the world are suffering from diabetes and the number is rising. The global market of self-monitoring devices will reach $12.2 billion by the year 2017. DIA-VIT device will increase quality of life for diabetes patients, enable early, simple and accurate diagnostic and reduce costs of the diabetes health care. Our innovation will represent business opportunity for producers/suppliers and distributors of the device.

Target users for DIA-VIT device are diabetes patients, physically active and quality-of-life-aware population. Market segment is age 25-45, geographical areas are developed markets of EU and US, and later on also other markets.

The entrepreneurial team who worked together towards the currently developed minimum viable product consists of experts from different fields (R&D, sales, marketing, finance). Within Feasibility study we will assess technical, operational, legal, timing aspects of the project and develop business model and commercialization plan. We are determined to bring the DIA-VIT non-invasive glucose self-monitoring device to market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DIA-VIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DIA-VIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

RESHAPE (2019)

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials

Read More